Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis

Hepatology

Volumn 61, Issue 6, 2015, Pages 1809-1820

  Jang, Jeong Won ^a,i   Choi, Jong Young ^a,i   Kim, Young Seok ^b,i   Woo, Hyun Young ^c,i   Choi, Sung Kyu ^d,i   Lee, Chang Hyeong ^e,i   Kim, Tae Yeob ^f,i   Sohn, Joo Hyun ^f,i   Tak, Won Young ^g,i   Han, Kwang Hyub ^h,i  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

^c Pusan National University Hospital   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e Catholic University of Daegu   (South Korea)

^f Hanyang University Guri Hospital   (South Korea)

^g Kyungpook National University Hospital   (South Korea)

^h Yonsei University College of Medicine   (South Korea)

ⁱ Liver Cirrhosis Clinical Research Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CLEVUDINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; SEROCONVERSION; SURVIVAL; THERAPY DELAY; TREATMENT OUTCOME; VIREMIA; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; EPIDEMIOLOGY; HEPATITIS B, CHRONIC; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; SOUTH KOREA; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPENSITY SCORE; PROSPECTIVE STUDIES; REPUBLIC OF KOREA;

EID: 84929606836     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27723     Document Type: Article

References (25)

1. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
2. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006;26:142-152.
3. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-1635.
4. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995;21:77-82.
5. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442-450.
6. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174.
7. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
8. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719-727.
9. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-182.
10. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
11. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91-100.
12. Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012;19:732-743.
13. Bae SH, Yoon SK, Choi JY, Jang JW, Cho SH, Yang JM, et al. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis. J Gastroenterol Hepatol 2005;20:1527-1532.
14. Woo HY, Jang JW, Choi JY, Kim SG, Lee CH, Shon JH, et al. Mode of cirrhosis related complication in Korean patients with liver cirrhosis-a prospective multicenter cohort study. Hepatology 2012;56:951A.
15. Jang JW, Chun JY, Park YM, Shin SK, Yoo W, Kim SO, et al. Mutational complex genotype of the hepatitis B virus X /precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci 2012;103:296-304.
16. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-176.
17. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
18. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-283.
19. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
20. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
21. Bae SH, Yoon SK, Jang JW, Kim CW, Nam SW, Choi JY, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005;20:816-820.
22. Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012;35:674-689.
23. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
24. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010;53:348-356.
25. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-1077.